<?xml version='1.0' encoding='utf-8'?>
<document id="32114507"><sentence text="Role of OATP2B1 in drug absorption and drug-drug interactions."><entity charOffset="8-15" id="DDI-PubMed.32114507.s1.e0" text="OATP2B1" /></sentence><sentence text="The organic anion transporting polypeptide OATP2B1 is localized on the basolateral membrane of hepatocytes and is expressed in enterocytes" /><sentence text=" Based on its distribution pattern and functional similarity to OATP1B-type transporters, OATP2B1 might have a role in the absorption and disposition of a range of xenobiotics" /><sentence text=" Although several prescription drugs, including HMG-CoA inhibitors (statins) such as fluvastatin, are OATP2B1 substrates in vitro, evidence supporting the in vivo relevance of this transporter remains limited, and most has relied on substrate-inhibitor interactions resulting in altered pharmacokinetic properties of the victim drugs"><entity charOffset="85-96" id="DDI-PubMed.32114507.s4.e0" text="fluvastatin" /></sentence><sentence text=" In order to address this knowledge deficit, we developed and characterized an OATP2B1-deficient mouse model and evaluated the impact of this transporter on the absorption and disposition of fluvastatin"><entity charOffset="191-202" id="DDI-PubMed.32114507.s5.e0" text="fluvastatin" /></sentence><sentence text=" Consistent with the intestinal localization of OATP2B1, we found that the genetic or pharmacological inhibition of OATP2B1 was associated with decreased absorption of fluvastatin by 2- to 3-fold"><entity charOffset="168-179" id="DDI-PubMed.32114507.s6.e0" text="fluvastatin" /></sentence><sentence text=" The availability of a viable OATP2B1-deficient mouse model provides an opportunity to unequivocally determine the contribution of this transporter to the absorption and drug-drug interaction potential of drugs" /><sentence text=" SIGNIFICANCE STATEMENT: The current investigation suggests that OATP2B1-deficient mice provide a valuable tool to study the in vivo importance of this transporter" /><sentence text=" In addition, our studies have identified novel potent inhibitors of OATP2B1 among the class of tyrosine kinase inhibitors, a rapidly expanding class of drugs used in various therapeutic areas that may cause drug-drug interactions with OATP2B1 substrates"><entity charOffset="96-104" id="DDI-PubMed.32114507.s9.e0" text="tyrosine" /></sentence><sentence text="" /></document>